KYMR Kymera Therapeutics, Inc.
Price Chart
Executive Summary
Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, showing safety and PK/PD results consistent with prior studies. The data supports global Phase 2b trials (BROADEN2 in atopic dermatitis, BREADTH in asthma) that are ongoing with readouts expected by mid-2027 and late 2027, respectively. This is an incremental data update with no new efficacy or regulatory catalyst — a routine clinical-stage update for a $6.8B biotech.
Actionable Insight
This is a routine clinical update with no material new data — the stock is unlikely to move on this announcement alone. Monitor Phase 2b data readouts in mid-2027 (AD) and late 2027 (asthma) as the next major catalysts. No trading action warranted.
Key Facts
- Phase 1 study in 24 healthy Japanese adults showed median STAT6 degradation ≥98% at both dose levels at Day 7, consistent with prior non-Japanese studies.
- KT-621 was well tolerated with a favorable safety profile across both doses.
- Parallel Phase 2b trials BROADEN2 (atopic dermatitis) and BREADTH (asthma) are ongoing; data expected by mid-2027 and late 2027, respectively.
- No new efficacy data, regulatory milestone, or financial guidance was disclosed in this press release.
Financial Impact
No financial figures disclosed; this is a clinical data update with no immediate revenue or cost impact.
Risk Factors
- Phase 2b data may fail to replicate Phase 1 efficacy or safety signals.
- Competition from other oral STAT6/Type 2 inflammation programs (e.g., from Roche, Sanofi) could limit commercial potential.
- Cash burn from ongoing trials without near-term revenue may pressure the stock if financing is needed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310977 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Press Release
| $82.96 awaiting T+5 | awaiting T+5 | — | $86.21 (+3.91%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $82.43 awaiting T+5 | awaiting T+5 | — | $86.21 (+4.59%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $79.19 awaiting T+5 | awaiting T+5 | — | $86.21 (+8.86%) |
|
Jun 8, 2026
6d ago
|
Press Release
| $73.80 awaiting T+5 | awaiting T+5 | — | $86.21 (+16.81%) |
|
May 26, 2026
19d ago
|
144
| $81.70 $73.21 | ▼ −10.39% | ▼ −10.86% | $86.21 (+5.51%) |
|
May 15, 2026
4w ago
|
Press Release
| $82.21 $78.89 | ▼ −4.04% | ▼ −5.00% | $86.21 (+4.86%) |
|
May 11, 2026
4w ago
|
144
| $83.55 $79.67 | ▼ −4.64% | ▼ −4.72% | $86.21 (+3.18%) |
|
Apr 23, 2026
7w ago
|
Press Release
| $87.17 $81.51 | ▼ −6.49% | ▼ −7.97% | $86.21 (−1.11%) |
|
Apr 15, 2026
8w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $86.21 (+0.08%) |
|
Apr 15, 2026
8w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $86.21 (+0.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access